Ziopharm Oncology (ZIOP) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 7, 2020 4:06 PM EDTRegulatory discussions with FDA advance Ziopharm TCR-T IND process Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regenerons Libtayo®;Controlled IL-12 clinical data update at ASCO 2020 Work restrictions at NCI and MD Anderson impacting clinical trials;Ziopharm working to minimize delays Prioritizing Greater China CAR-T clinical trial given advancements Balance sheet strengthened in Q1; cash of $171 million to fund operations into mid-2022
Company to host conference call and webcast today, May 7, at 4:30 p.m. EDT
BOSTON, May 07, 2020... More
